Загадочный *Achromobacter*

Игорь Викторович Чеботарь; Ю.А.  Бочарова

doi:10.36488/cmac.2022.1.4-13

Загадочный Achromobacter

Клиническая микробиология и антимикробная химиотерапия. 2022; 24(1):4-13

Чеботарь И.В., Бочарова Ю.А.

10.36488/cmac.2022.1.4-13

Achromobacter ахромобактерии антибиотикорезистентность диагностика инфекция

Раздел

Болезни и возбудители

Тип

Обзор

Публикация

Клиническая микробиология и антимикробная химиотерапия. 2022; 24(1):4-13

Аннотация Авторы Литература PDF Статистика Репринты

Аннотация

Данный обзор литературы посвящен описанию микробиологических, патогенетических и резистентных характеристик Achromobacter spp. Являясь типичными оппортунистическими патогенами, ахромобактерии могут вызывать тяжелые и даже фатальные инфекции. Авторы акцентируют внимание на критическом анализе современных знаний о молекулярных основах клинически важных свойств ахромобактерий. Представления о факторах патогенности ахромобактерий во многом являются предсказательными, валидизация вирулентного потенциала многих факторов не подтверждалась в условиях классических экспериментов in vitro и in vivo. Ахромобактерии обладают широким спектром природной устойчивости к антибиотикам и быстро приобретают адаптивную резистентность к ним. При этом перечень антибиотиков, в отношении которых возможна интерпретация чувствительности для ахромобактерий, ограничивается лишь меропенемом, пиперациллином/тазобактамом и триметопримом/сульфаметоксазолом. Главный практический вывод заключается в том, что существует острая необходимость в разработке доступных и качественных методов быстрой видовой идентификации Achromobacter spp.

Чеботарь Игорь Викторович

nizarnn@yandex.ru

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия

Бочарова Ю.А.

1. Somayaji R., Stanojevic S., Tullis D.E., Stephenson A.L., Ratjen F., Waters V. Clinical outcomes associated with Achromobacter species infection in patients with cystic fibrosis. Ann Am Thorac Soc. 2017;14(9):1412-1418. DOI: 10.1513/AnnalsATS.201701-071OC
2. Marsac C., Berdah L., Thouvenin G., Sermet-Gaudelus I., Corvol H. Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis. ERJ Open Research. 2021;7(2):00076-2021. DOI: 10.1183/23120541.00076-2021
3. Swenson C.E., Sadikot R.T. Achromobacter respiratory infections. Ann Am Thorac Soc. 2015;12:252-258. DOI: 10.1513/AnnalsATS.201406-288FR
4. Marion-Sanchez K., Lion F., Olive C., Cailleaux G., Roques F. Mediastinitis superinfected by Achromobacter xylosoxidans. A case report. J Infect Chemother. 2018;24:987-989. DOI: 10.1016/j.jiac.2018.05.005
5. Asano K., Tada S., Matsumoto T., Miyase S., Kamio T., KSakurai K., Lida M. A novel bacterium Achromobacter xylosoxidans as a cause of liver abscess: three case reports. J Hepatol. 2005;43:362-365. DOI: 10.1016/j.jhep.2005.03.031
6. Ronin E., Derancourt C., Cabié A., Marion-Sanchez K. Achromobacter spp. Surgical site infections: a systematic review of case reports and case series. Microorganisms. 2021;9(12):2471. DOI: 10.3390/microorganisms9122471
7. Bergey D.H., Harrison F.C., Breed R.S., Hammer B.W., Huntoon F.M. Bergey’s manual of determinative bacteriology. 1st Ed. The Williams & Wilkins Co, Baltimore; 1923. 442 p.
8. Eisenberg J. Bakteriologische Diagnostik, Hilfstabellen zum Gebrauche beim Praktischen Arbeiten. 3 Aufl. Leopold Voss, Hamburg; 1891. 509 S.
9. Lehmann K.B., Neumann R.O. Atlas und Grundriss der Bakteriologie und Lehrbuch der speciellen bacteriologischen Diagnostik. Teil II. Verlag von Lehmann J.F., Munich; 1896. 448 S.
10. Wells N.A., ZoBell C.E. Achromobacter ichthyodermis, n. sp., the etiological agent of an infectious dermatitis of certain marine fishes. Proc Natl Acad Sci U S A. 1934;20(2):123-126. DOI: 10.1073/pnas.20.2.123
11. Dereux J. Lymphocytic meningitis caused by a germ of the family Achromobacteriaceae. Bull Acad Natl Med. 1954;138(7-8):118-120. PMID: 13160586
12. Krieg N.R. Holt J.G. Bergey’s Manual of Systematic Bacteriology. 1st Ed., Vol. 1. Williams and Wilkins, Baltimore; 1984. 964 p.
13. Buchanan R.E., Gibbons N.R. Bergey's Manual of Determinative Bacteriology. 8th Ed., Williams & Wilkins, Baltimore; 1974. 1268 p.
14. Busse H.-J., Auling G. Achromobacter. In: Bergey’s Manual of Systematics of Archaea and Bacteria; 2015. DOI: 10.1002/9781118960608.gbm00926
15. International Committee on Systematics of Prokaryotes (ICSP). Available at: www.the-icsp.org. Accessed January 2022.
16. International code of nomenclature of Prokaryotes. Int J Syst Evol Microbiol. 2019;69(1A):S1-S111. DOI: 10.1099/ijsem.0.000778
17. Vandamme P., Moore E.R.B., Cnockaert M., Peeters C., Svensson-Stadler L., Houf K., et al. Classification of Achromobacter genogroups 2, 5, 7 and 14 as Achromobacter insuavis sp. nov., Achromobacter aegrifaciens sp. nov., Achromobacter anxifer sp. nov. and Achromobacter dolens sp. nov., respectively. Syst Appl Microbiol. 2013;36(7):474-482. DOI: 10.1016/j.syapm.2013.06.005
18. Vandamme P., Moore E.R.B., Cnockaert M., De Brandt E., Svensson-Stadler L., Houf K., et al. Achromobacter animicus sp. nov., Achromobacter mucicolens sp. nov., Achromobacter pulmonis sp. nov. and Achromobacter spiritinus sp. nov., from human clinical samples. Syst Appl Microbiol. 2013;36(1):1-10. DOI: 10.1016/j.syapm.2012.10.003
19. Vandamme P.A., Peeters C., Inganäs E., Cnockaert M., Houf K., Spilker T., et al. Taxonomic dissection of Achromobacter denitrificans Coenye et al. 2003 and proposal of Achromobacter agilis sp. nov., nom. rev., Achromobacter pestifer sp. nov., nom. rev., Achromobacter kerstersii sp. nov. and Achromobacter deleyi sp. nov. Int J Syst Evol Microbiol. 2016;66(9):3708-3717. DOI: 10.1099/ijsem.0.001254
20. Coenye T., Vancanneyt M., Cnockaert M.C., Falsen E., Swings J., Vandamme P. Kerstersia gyiorum gen. nov., sp. nov., a novel Alcaligenesfaecalis-like organism isolated from human clinical samples, and reclassification of Alcaligenes denitrificans Ruger and Tan 1983 as Achromobacter denitrificans comb. nov. Int J Syst Evol Microbiol. 2003;53:1825-1831. DOI: 10.1099/ijs.0.02609-0
21. Coenye T., Vancanneyt M., Falsen E., Swings J., Vandamme P. Achromobacter insolitus sp. nov. and Achromobacter spanius sp. nov., from human clinical samples. Int J Syst Evol Microbiol. 2003;53:1819-1824. DOI: 10.1099/ijs.0.02698-0
22. Gomila M., Tvrzová L., Teshim A., Sedlácek I., GonzálezEscalona N., González-Escalona N., et al. Achromobacter marplatensis sp. nov., isolated from a pentachlorophenolcontaminated soil. Int J Syst Evol Microbiol. 2011;61:22312237. DOI: 10.1099/ijs.0.025304-0
23. Yabuuchi E., Kawamura Y., Kosako Y., Ezaki T. Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (packer and Vishniac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov., and Achromobacter xylosoxidans subsp. denitrificans (Rüger and Tan) comb. nov. Microbiol Immunol. 1998;42(6):429-438. DOI: 10.1111/j.1348-0421.1998.tb02306.x
24. Kazemzadeh S., Naghavi N.S., Emami-Karvani Z., Emtiazi G., Fouladgar M. Production of glycolipid biosurfactant during crude oil degradation by the novel indigenous isolated Achromobacter kerstersii LMG3441. Water Sci Technol. 2020;82(10):2134-2147. DOI: 10.2166/wst.2020.474
25. Genome Taxonomy Database (GTDB). Available at: https://gtdb.ecogenomic.org/. Accessed January 2022.
26. Abdouchakour F., Dupont C., Grau D., Aujoulat F., Mournetas P., Marchandin H., et al. Pseudomonas aeruginosa and Achromobacter sp. clonal selection leads to successive waves of contamination of water in dental care units. Appl Environ Microbiol. 2015;81(21):7509-7524. DOI: 10.1128/AEM.01279-15
27. McBain A.J., Bartolo R.G., Catrenich C.E., Charbonneau D., Ledder R.G., Price B.B., Gilbert P. Exposure of sink drain microcosms to triclosan: population dynamics and antimicrobial susceptibility. Appl Environ Microbiol. 2003;69(9):5433-5442. DOI: 10.1128/AEM.69.9.5433-5442.2003
28. Amoureux L., Bador J., Fardeheb S., Mabille C., Couchot C., Massip C., et al. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol. 2013;79(23):7142-7149. DOI: 10.1128/AEM.02293-13
29. Edwards B.D., Greysson-Wong J., Somayaji R., Waddell B., Whelan F.J., Storey D.G., et al. Prevalence and outcomes of Achromobacter species infections in adults with cystic fibrosis: a North American cohort study. J Clin Microbiol. 2017;55(7):2074-2085. DOI: 10.1128/JCM.02556-16
30. Filipic B., Malesevic M., Vasiljevic Z., Lukic J., Novovic K., Kojic M., Jovcic B. Uncovering differences in virulence markers associated with Achromobacter species of CF and non-CF origin. Front Cell Infect Microbiol. 2017;7:224. DOI: 10.3389/fcimb.2017.00224
31. Vijay A.K., Willcox M.D. Adhesion of Stenotrophomonas maltophilia, Delftia acidovorans, and Achromobacter xylosoxidans to contact lenses. Eye Contact Lens. 2018;44:S120-S126. DOI: 10.1097/ICL.0000000000000425
32. Nejidat A., Saadi I., Ronen Z. Effect of flagella expression on adhesion of Achromobacter piechaudii to chalk surfaces. J Appl Microbiol. 2008;105(6):2009-2014. DOI: 10.1111/j.1365-2672.2008.03930.x
33. Mantovani R.P., Levy C.E., Yano T. A heat-stable cytotoxic factor produced by Achromobacter xylosoxidans isolated from Brazilian patients with CF is associated with in vitro increased proinflammatory cytokines. J Cyst Fibros. 2012;11(4):305-311. DOI: 10.1016/j.jcf.2012.02.002
34. Veschetti L., Sandri A., Patuzzo C., Melotti P., Malerba G., Lleo M.M. Genomic characterization of Achromobacter species isolates from chronic and occasional lung infection in cystic fibrosis patients. Microb Genom. 2021;7(7):000606. DOI: 10.1099/mgen.0.000606
35. Virulence Factor Database (VFDB). Available at: www.mgc.ac.cn/VFs. Accessed January 2022.
36. Rapid Annotations using Subsystems Technology (RAST). Available at: http://RAST.nmpdr.org/. Accessed January 2022.
37. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.Ø., Bjarnsholt T., Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2010;9(1):51-58. DOI: 10.1016/j.jcf.2009.10.005
38. Jakobsen T.H., Hansen M.A., Jensen P.Ø., Hansen L., Riber L., Cockburn A., et al. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. PloS One. 2013;8(7):e68484. DOI: 10.1371/journal.pone.0068484
39. Veschetti L., Sandri A., Krogh Johansen H., Lleò M.M., Malerba G. Hypermutation as an evolutionary mechanism for Achromobacter xylosoxidans in cystic fibrosis lung infection. Pathogens. 2020;9(2):72. DOI: 10.3390/pathogens9020072
40. Ridderberg W., Nielsen S.M., Nørskov-Lauritsen N. Genetic adaptation of Achromobacter sp. during persistence in the lungs of cystic fibrosis patients. PLoS One. 2015;10(8):e0136790. DOI: 10.1371/journal.pone.0136790
41. Li X., Hu Y., Gong J., Zhang L., Wang G. Comparative genome characterization of Achromobacter members reveals potential genetic determinants facilitating the adaptation to a pathogenic lifestyle. Appl Microbiol Biotechnol. 2013;97(14):6413-6425. DOI: 10.1007/s00253-013-5018-3
42. Tessmer M.H., Anderson D.M., Pickrum A.M., Riegert M.O., Frank D.W. Identification and verification of ubiquitin-activated bacterial phospholipases. J Bacteriol. 2019;201(4):e00623-18. DOI: 10.1128/JB.00623-18
43. Pickrum A.M., DeLeon O., Dirck A., Tessmer M.H., Riegert M.O., Biller J.A., et al. Achromobacter xylosoxidans cellular pathology is correlated with activation of a type III secretion system. Infect Immun. 2020;88(7):e00136-20. DOI: 10.1128/IAI.00136-20
44. Isogai H., Isogai E., Fujii N., Oguma K., Chang K.L., Deguchi E., et al. Biological effects of lipopolysaccharide from Achromobacter stenohalis on lymphocytes and macrophages. Nihon Juigaku Zasshi. 1989;51(5):1003-1010. DOI: 10.1292/jvms1939.51.1003
45. Orellana-Peralta F., Jacinto M., Pons M.J., Gomes C., Bada C., Reyes I., et al. Characterization of two Achromobacter xylosoxidans isolates from patients with pertussis-like symptoms. Asian Pac J Trop Med. 2015;8(6):464-467. DOI: 10.1016/j.apjtm.2015.05.013
46. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Intrinsic Resistance and Unusual Phenotypes. Version 3.3, October 2021. Available at: www.eucast.org/expert_rules_and_intrinsic_resistance/. Accessed January 2022.
47. Doi Y., Poirel L., Paterson D.L., Nordmann P. Characterization of a naturally occurring classD β-lactamase from Achromobacter xylosoxidans. Antimicrob Agents Chemother. 2008;52(6):1952-1956. DOI: 10.1128/AAC.01463-07
48. Levesque R., Letarte R., Pechère J.-C. Comparative study of the beta-lactamase activity found in Achromobacter. Can J Microbiol. 1983;29(7):819-826. DOI: 10.1139/m83133
49. Decré D., Arlet G., Bergogne-Berezin E., Philippon A. Identification of a carbenicillin-hydrolyzing β-lactamase in Alcaligenes denitrificans subsp. xylosoxydans. Antimicrob Agents Chemother. 1995;39(3):771-774. DOI: 10.1128/AAC.39.3.771
50. Philippon A., Mensah K., Fournier G., Freney J. Two resistance phenotypes to β-lactams of Alcaligenes denitrificans subsp. xylosoxydans in relation to β-lactamase types. J Antimicrob Chemother. 1990;25(4):698-700. DOI: 10.1093/jac/25.4.698
51. Fujii T., Sato K., Inoue M., Mitsuhashi S. Purification and properties of a β-lactamase from Alcaligenes dentrificans subsp. xylosoxydans. J Antimicrob Chemother. 1985;16(3):297-304. DOI: 10.1093/jac/16.3.297
52. Bador J., Amoureux L., Duez J.M., Drabowicz A., Siebor E., Llanes C., Neuwirth C. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob Agents Chemother. 2011;55(10):4912-4914. DOI: 10.1128/AAC.00341-11
53. Bador J., Amoureux L., Blanc E., Neuwirth C. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrob Agents Chemother. 2013;57(1):603-605. DOI: 10.1128/AAC.01243-12
54. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022. Available at: www. eucast.org/clinical_breakpoints/. Accessed January 2022.
55. Manohar P., Leptihn S., Lopes B. S., Nachimuthu R. Dissemination of carbapenem resistance and plasmids encoding carbapenemases in Gram-negative bacteria isolated in India. JAC Antimicrob Resist. 2021;3(1):dlab015. DOI: 10.1093/jacamr/dlab015
56. Potron A., Fournier D., Emeraud C., Triponney P., Plésiat P., Naas T., Dortet L. Evaluation of the immunochromatographic NG-Test Carba 5 for rapid identification of carbapenemase in nonfermenters. Antimicrob Agents Chemother. 2019;63(9):e00968-19. DOI: 10.1128/AAC.00968-19
57. Vali P., Shahcheraghi F., Seyfipour M., Zamani M.A., Allahyar M.R., Feizabadi M.M. Phenotypic and genetic characterization of carbapenemase and ESBLs producing gram-negative bacteria (GNB) isolated from patients with cystic fibrosis (CF) in Tehran hospitals. J Clin Diagn Res. 2014;8(1):26-30. DOI: 10.7860/JCDR/2014/6877.3916
58. Yamamoto M., Matsumura Y., Gomi R., Matsuda T., Tanaka M., Nagao M., et al. Interspecies dissemination of a mobilizable plasmid harboring bla IMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016;60(9):5412-5419. DOI: 10.1128/AAC.00933-16
59. Chen Z., Fang H., Wang L., Sun F., Wang Y., Yin Z., et al. IMP-1 encoded by a novel Tn 402-like class 1 integron in clinical Achromobacter xylosoxidans, China. Sci Rep. 2014;4:7212. DOI: 10.1038/srep07212
60. Fleurbaaij F., Henneman A.A., Corver J., Knetsch C.W., Smits W.K., Nauta S.T., et al. Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans. Sci Rep. 2018;8:8181. DOI: 10.1038/s41598-018-26079-z
61. Traglia G.M., Almuzara M., Merkier A K., Adams C., Galanternik L., Vay C., et al. Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer. Curr Microbiol. 2012;65(6):673-678. DOI: 10.1007/s00284-0120213-5
62. Khademi S.H., Gabrielaite M., Paulsson M., Knulst M., Touriki E., Marvig R.L., et al. Genomic and phenotypic evolution of Achromobacter xylosoxidans during chronic airway infections of patients with cystic fibrosis. mSystems. 2021;6(3):e00523-21. DOI: 10.1128/mSystems.00523-21
63. Miller A.K., Brannon M.K., Stevens L., Johansen H.K., Selgrade S.E., Miller S.I., et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2011;55(12):5761-5769. DOI: 10.1128/AAC.05391-11
64. Fabbri A., Tacchella A., Manno G., Viscoli C., Palmero C., Gargani G.F. Emerging microorganisms in cystic fibrosis. Chemioterapia. 1987;6(1):32-37. PMID: 3103930
65. Elborn J.S. Cystic fibrosis. Lancet. 2016;388(10059):25192531. DOI: 10.1016/S0140-6736(16)00576-6
66. Karanth S.S., Gupta A., Prabhu M. Community acquired bilateral upper lobe pneumonia with acute adrenal insufficiency: a new face of Achromobacter xylosoxidans. Australas Med J. 2012;5(10):531-533. DOI: 10.4066/AMJ.2012.1279
67. Shimamura T., Yamashita S., Ryuujin S., Ogata T., Yamashita T., Sato A., Hitomi S. Hematogenous pleural infection caused by Achromobacter xylosoxidans in a patient undergoing maintenance hemodialysis. J Infect Chemother. 2020;26(4):389-392. DOI: 10.1016/j.jiac.2019.11.006
68. Tena D., González-Praetorius A., Pérez-Balsalobre M., Sancho O., Bisquert J. Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand J Infect Dis. 2008;40(2):84-87. DOI: 10.1080/00365540701558714
69. Sgrelli A., Mencacci A., Fiorio M., Orlandi C., Baldelli F., De Socio G.V. Achromobacter denitrificans renal abscess. New Microbiol. 2012;35(2):245-247. PMID: 22707140
70. Vinod V., Kumar A., Sanjeevan K.V., Dinesh K.R., Karim S. Perinephric abscess due to Achromobacter xylosoxidans following de-roofing of renal cyst. Surg Infect (Larchmt). 2013;14(4):422-423. DOI: 10.1089/sur.2012.142
71. Al-Jasser A.M., Al-Anazi K.A. Complicated septic shock caused by Achromobacter xylosoxidans bacteremia in a patient with acute lymphoblastic leukaemia. Libyan J Med. 2007;2(4):218-219. DOI: 10.4176/070617
72. Turel O., Kavuncuoglu S., Hosaf E., Ozbek S., Aldemir E., Uygur T., et al. Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome. Braz J Infect Dis. 2013;17(4):450-454. DOI: 10.1016/j.bjid.2013.01.008
73. Nichols K.R., Knoderer C.A., Jackson N.G., Manaloor J.J., Christenson J.C. Success with extended-infusion meropenem after recurrence of baclofen pumprelated Achromobacter xylosoxidans meningitis in an adolescent. J Pharm Pract. 2015;28(4):430-433. DOI: 10.1177/0897190015585757
74. Rovlias A. A rare case of Achromobacter species subdural empyema and brain abscess in an adult patient with hematologic malignancy. Asian J Neurosurg. 2020;5(1):245-246. DOI: 10.4103/ajns.AJNS_373_19
75. Eshwara V.K., Mukhopadhyay C., Mohan S., Prakash R., Pai G. Two unique presentations of Achromobacter xylosoxidans infections in clinical settings. J Infect Dev Ctries. 2011;5(2):138-141. DOI: 10.3855/jidc.1258
76. Crosby M.D., Petropolis A.A., Mackey V.T., Culpepper K.S. An unusual skin infection with Achromobacter xylosoxidans. Cutis. 2020;106(4):2110-2112. DOI: 10.12788/cutis.0087
77. Tena D., Martínez N.M.., Losa C., Solís S. Skin and soft tissue infection caused by Achromobacter xylosoxidans: report of 14 cases. Scand J Infect Dis. 2014;46(2):130135. DOI: 10.3109/00365548.2013.857043
78. Alkindi S., Matwani S., Al-Maawali A., Al-Maskari B., Pathare A. Complications of PORT-A-CATH® in patients with sickle cell disease. J Infect Public Health. 2012;5(1):5762. DOI: 10.1016/j.jiph.2011.10.004
79. Ahmed M.S., Nistal C., Jayan R., Kuduvalli M., Anijeet H.K. Achromobacter xylosoxidans, an emerging pathogen in catheter-related infection in dialysis population causing prosthetic valve endocarditis: a case report and review of literature. Clin Nephrol. 2009;71(3):350-354. DOI: 10.5414/cnp71350
80. de Castro R.L., de Alcantara Lima N., da Costa Lino D.O., Melgar T.A. A rare case of non-prosthetic aortic valve infectious endocarditis caused by Achromobacter xylosoxidans. Am J Case Rep. 2020;21:e923031-1. DOI: 10.12659/AJCR.923031
81. Van Hal S., Stark D., Marriott D., Harkness J. Achromobacter xylosoxidans subsp. xylosoxidans prosthetic aortic valve infective endocarditis and aortic root abscesses. J Med Microbiol. 2008;57(4):525-527. DOI: 10.1099/jmm.0.47496-0
82. Bc D., Bernard S.H., Vv V., Gp W., Jm J. The role of Achromobacter xylosoxidans positive sinus cultures in patients with refractory chronic rhinosinusitis. Online J Otolaryngol. 2018;8(2):172.
83. Cheong R.C.T., Harding L. Septic arthritis of the temporomandibular joint secondary to acute otitis media in an adult: a rare case with Achromobacter xylosoxidans. Case Rep Otolaryngol. 2017;2017:3641642. DOI: 10.1155/2017/3641642
84. Lazzarini T.A., Al-Khersan H., Patel N.A., Yannuzzi N.A., Martinez J.D., Altamirano D., et al. Chronic, recurrent bacterial endophthalmitis caused by Achromobacter xylosoxidans: clinical features and management. Int Med Case Rep J. 2020;13:265-269. DOI: 10.2147/IMCRJ.S259899
85. Spierer O., Monsalve P.F., O’Brien T.P., Alfonso E.C., Gologorsky D., Miller D. Clinical features, antibiotic susceptibility profiles, and outcomes of infectious keratitis caused by Achromobacter xylosoxidans. Cornea. 201;35(5):626-630. DOI: 10.1097/ICO.0000000000000798
86. Cankaya E., Keles M., Gulcan E., Uyanik A., Uyanik H. A rare cause of peritoneal dialysis-related peritonitis: Achromobacter denitrificans. Perit Dial Int. 2014;34(1):135137. DOI: 10.3747/pdi.2013.00063
87. Kawaguchi Y., Hayashi S., Kawagoe N., Igawa T. Retroperitoneal abscess due to Achromobacter xylosoxidans presenting as femoral pain. Urol Case Rep. 2020;31:101153. DOI: 10.1016/j.eucr.2020.101153
88. Barton L.L., Hoddy D.M. Osteomyelitis due to Achromobacter xylosoxidans. Clin Infect Dis. 1993;17(2):296-297. DOI: 10.1093/clinids/17.2.296
89. Carroll M.B., Forgione M. Achromobacter xylosoxidans presenting as a suprapatellar abscess and polyarthritis. J Clin Rheumatol. 2010;16(1):45-46. DOI: 10.1097/RHU.0b013e3181c7e4c8
90. Patel P.K., von Keudell A., Moroder P., Appleton P., Wigmore R., Rodriguez E.K. Recurrent septic arthritis due to Achromobacter xylosoxidans in a patient with granulomatosis with polyangiitis. Open Forum Infect Dis. 2015;2(4):ofv145. DOI: 10.1093/ofid/ofv145
91. Haviari S., Cassier P., Dananché C., Hulin M., Dauwalder O., Rouvière O., et al. Outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi infections after prostate biopsies, France, 2014. Emerg Infect Dis. 2016;22(8):1412-1419. DOI: 10.3201/eid2208.151423
92. Papalia M., Steffanowski C., Traglia G., Almuzara M., Martina P., Galanternik L., et al. Diversity of Achromobacter species recovered from patients with cystic fibrosis, in Argentina. Rev Argent Microbiol. 2020;52(1):13-18. DOI: 10.1016/j.ram.2019.03.004
93. Rotter J., Graffeo C.S., Perry A., Gilder H.E., Wilson J.W., Link M.J. Polymicrobial intracerebral abscess growing Mycobacterium avium complex and Achromobacter xylosoxidans: case report and literature review. World Neurosurg. 2020;141:441-447. DOI: 10.1016/j.wneu.2020.05.283
94. Sandri A., Haagensen J.A.J., Veschetti L., Johansen H.K., Molin S., Malerba G., et al. Adaptive interactions of Achromobacter spp. with Pseudomonas aeruginosa in cystic fibrosis chronic lung co-infection. Pathogens. 2021;10(8):978. DOI: 10.3390/pathogens10080978
95. Habib S., Fuca N., Azam M., Siddiqui A.H., Rajdev K., Chalhoub M. Achromobacter xylosoxidans/denitrificans bacteremia and subsequent fatal Escherichia coli/Streptococcus anginosus pleural empyema. Respir Med Case Rep. 2018;25:311-313. DOI: 10.1016/j.rmcr.2018.10.010
96. Garrigos T., Neuwirth C., Chapuis A., Bador J., Amoureux L., Collaborators. Development of a database for the rapid and accurate routine identification of Achromobacter species by matrix-assisted laser desorption/ionization–timeof-flight mass spectrometry (MALDI-TOF MS). Clin Microbiol Infect. 2021;27(1):126.e1-126.e5. DOI: 10.1016/j.cmi.2020.03.031
97. Spilker T., Vandamme P., Lipuma J.J. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros. 2013;12:298-301. DOI: 10.1016/j.jcf.2012.10.002
98. Spilker T., Vandamme P. and Lipuma J.J. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol. 2012;50(9):3010-3015. DOI: 10.1128/JCM.00814-12

Просмотров

0 Аннотация

0 PDF

0 Цитирования

Загадочный Achromobacter

Аннотация

Просмотров

Поделились

Процитировали Crossref